Clinical trials: Tauopathies
Alzheimer Disease
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
The purpose of this study is to determine the safety and efficacy of TRx0237 16 mg/day and 8 mg/day in the treatment of subjects with Alzheimer's Disease compared to placebo.
- Trial name
- NCT03446001
- Testing
- TRx0237 16 mg/day, Control, TRx0237 8 mg/day
- Where
- 103 sites in United States, Belgium and 6 more
- Volunteers
- 598 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer's Disease
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
The investigators hypothesize that Nilotinib will be safe in individuals with mild to moderate AD. Specifically, investigators hypothesize that low daily oral doses of Nilotinib will lead to CSF penetration, CNS Abl inhibition…
- Trial name
- AD (NCT02947893)
- Testing
- Nilotinib Capsule(s) Once a Day by Mouth
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Georgetown University
Alzheimer's Disease
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind…
- Trial name
- NCT02586909
- Testing
- RVT-101 35 mg tablets
- Where
- 169 sites in United States, Argentina and 17 more
- Volunteers
- 1,099 people
- Sponsor
- Axovant Sciences Ltd.
Dementia, Alzheimer Disease
Community-based Brain Health Program to Address Dementia Risk
This is a validation study to evaluate the acceptability, feasibility and preliminary efficacy of the Brain Health Program, a multimodal curriculum covering dementia risk factors and evidence-based change interventions.
- Trial name
- C-BBHP (NCT05529706)
- Testing
- Brain Health Program
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Posit Science Corporation
Stress, Carer Stress Syndrome
Tailored Health Self-Management Interventions for Highly Distressed Caregivers: Family Members of Persons With Dementia
How do different health self-management interventions (resourcefulness training or biofeedback training) compare to usual care (dementia education) in affecting the health risks, and physical and mental health, of family…
- Conditions
- Stress, Carer Stress Syndrome, Dementia, Alzheimer Disease
- Trial name
- NCT04247347
- Testing
- Biofeedback Training, Dementia Education, Resourcefulness Training
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Case Western Reserve University
Alzheimer Disease, Mild Cognitive Impairment
Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults
This study seeks to better understand how older adult aging-in-place/long term care decision making and implementation is impacted by age-related changes (e.g.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Long-Term Care Planning
- Trial name
- PYL (NCT03960476)
- Testing
- PlanYourLifespan.org
- Where
- United States
- Volunteers
- 293 people
- Sponsor
- Northwestern University
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Alzheimer's Disease
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo.
- Trial name
- NCT01193608
- Testing
- AAB-003 (PF-05236812)
- Where
- 29 sites in United States, South Korea
- Volunteers
- 88 people
- Sponsor
- Pfizer
Alzheimer's Disease
Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
Recent data show that marked cell damage precedes the clinical manifestation of Alzheimer's disease (AD). Hence, targeting populations at risk with pharmacological interventions is a possible strategy to lessen the burden of the…
- Trial name
- NCT00933608
- Testing
- memantine
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Alzheimer's Disease
A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease.
- Trial name
- NCT02431468
- Testing
- Bryostatin 1
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Neurotrope Bioscience, Inc.
Alzheimer's Disease
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
This study will evaluate the safety and Efficacy of donepezil in treatment of AD patients in China.
- Trial name
- STDMMAD (NCT02787746)
- Testing
- Donepezil
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Beijing Friendship Hospital
Alzheimer Disease
S-Equol in Alzheimer's Disease 2 Trial
By doing this study researchers hope to learn if S-equol, a compound that acts like estrogen in the body, causes an increase in mitochondrial activity.
- Trial name
- SEAD2 (NCT03101085)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Russell Swerdlow
Alzheimer's Disease, Frontotemporal Dementia, Behavioral Variant
Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
This pilot study aims to test clinical and connectivity changes following non-invasive stimulation of disease-specific networks in Alzheimer's disease (AD) and behavioral variant frontotemporal dementia (bvFTD).
- Trial name
- NetCogBs (NCT03422250)
- Testing
- transcranial direct current stimulation (tDCS)
- Where
- Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment
This study aims to develop and evaluate new in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT04206670
- Testing
- In-Home Technology System and Questionnaires, Waiting Control In-Home Technology System and Questionnaires
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Alzheimer Disease, Mild Memory Disturbance
The MObile AssessMENT of Behavioral and Psychological Symptoms of Dementia in Amnestic MCI and AD (MOMENT) Study
The purpose of this research study is to learn whether it is possible and useful for caregivers to report behavioral or psychological symptoms of people with mild memory problems or Alzheimer's disease through a smartphone mobile…
- Conditions
- Alzheimer Disease, Mild Memory Disturbance, Mild Cognitive Impairment
- Trial name
- MOMENT (NCT04482036)
- Testing
- Mobile Phone Application Assessments, Standard Assessments
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Indiana University
Alzheimer's Disease, Huntington's Disease
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).
- Trial name
- NCT00975481
- Testing
- dimebon, alprazolam
- Volunteers
- 36 people
- Sponsor
- Pfizer
Alzheimer Disease
Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization product+, in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00955409
- Testing
- ACC-001(3µg) + QS21, ACC-001(10µg) + QS21, ACC-001(30µg) + QS21
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
Alzheimers Disease
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD.
- Trial name
- SKYLINE (NCT05256134)
- Testing
- Gantenerumab
- Where
- 63 sites in United States, Argentina and 8 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
This is a multi-center, open-label, single-arm, prospective, phase IV trial, evaluating safety and efficacy of donepezil hydrochloride in patients with moderate to severe Alzheimer's disease.
- Trial name
- SAVE (NCT02097056)
- Testing
- Donepezil HCL
- Where
- 13 sites in South Korea
- Volunteers
- 171 people
- Sponsor
- Eisai Korea Inc.